

Petitioner,  
v.  
AMGEN INCORPORATED  
Patent Owner

---

U.S. Patent 7,829,595

---

**DECLARATION OF JENNIFER L. CALVERT**

Exhibit No.	Document Description
Ex. 1001	U.S. Patent No. 7,829,595 to Lawrence, <i>et al.</i> (“595 Patent” or Ex. 1001)
Ex. 1002	File History to the 595 Patent (“File History” or “Ex. 1002”)
Ex. 1003	U.S. Patent No. 6,211,244 to Van Wagenen, <i>et al.</i> (“Van Wagenen” or “Ex. 1003”)
Ex. 1004	U.S. Patent No. 5,162,117 to Stupak, <i>et al.</i> (“Stupak” or “Ex. 1004”)
Ex. 1005	European Patent Application No. 1 321 142 A1 by Vitzling, <i>et al.</i> (“Vitzling” or “Ex. 1005”)
Ex. 1006	U.S. Patent No. 5,879,706 to Carter, <i>et al.</i> (“Carter” or “Ex. 1006”)
Ex. 1007	Canadian Patent Application No. 2,004,565 by Chang, <i>et al.</i> (“Chang” or “Ex. 1007”)
Ex. 1008	U.S. Patent No. 8,703,196 to Babcock, <i>et al.</i> (“Babcock” or “Ex. 1008”)
Ex. 1009	U.S. Patent No. 6,733,780 to Tyler, <i>et al.</i> (“Tyler” or “Ex. 1009”)
Ex. 1010	U.S. Patent No. 4,931,286 to Johnson, <i>et al.</i> (“Johnson” or “Ex. 1010”)
Ex. 1011	Excerpts from The Pharmaceutical Codex: Principles and Practice of Pharmaceutics (12th ed.) (1994) (“Pharmaceutical Codex” or “Ex. 1011”)
Ex. 1012	Excerpts from the Handbook of Pharmaceutical Excipients (3rd ed.) (2000) (“HPE” or “Ex. 1012”)
Ex. 1013	Excerpts from Howard C. Ansel, <i>et al.</i> , Pharmaceutical Dosage Forms and Drug Delivery Systems (7th ed.) (1999) (“Ansel” or “Ex. 1013”)

	or “Ex. 1015”)
Ex. 1016	Particle Size – U.S. Sieve Series and Tyler Mesh Series Equivalents (2002; updated 2013), found at <a href="http://www.azom.com/article.aspx?ArticleID=1417">www.azom.com/article.aspx?ArticleID=1417</a> , last accessed August 7, 2015 (“Particle Size” or “Ex. 1016”)
Ex. 1017	New Agent Reduces PTH Levels in Hemodialysis Patients With Secondary Hyperparathyroidism, Formulary (April 2003) Vol. 38, p. 197 (“Formulary” or “Ex. 1017”)
Ex. 1018	J.C. Chaumeil, Micronization: A Method of Improving the Bioavailability of Poorly Soluble Drugs, METH. FIND. EXP. CLIN. PHARMACOL. (1998), pp. 211-215 (“Chaumeil” or “Ex. 1018”)
Ex. 1019	Excerpt from Sir Colin Dollery (ed.), Therapeutic Drugs, (1991) Vol. 2 (“Dollery” or “Ex. 1019”)
Ex. 1020	Gordon T. McInnes, <i>et al.</i> , Effect of Micronization on the Bioavailability and Pharmacologic Activity of Spironolactone, J. CLIN. PHARMACOL. 22 (1982), pp. 410-417 (“McInnes” or “Ex. 1020”)
Ex. 1021	Declaration of Walter G. Chambliss, Ph.D. (“Ex. 1021”)
Ex. 1022	Decision Granting <i>Inter Partes</i> Review as to U.S. Patent No. 6,821,975 (“Ex. 1022”)
Ex. 1023	Declaration of Jennifer L. Calvert (“Ex. 1023”)

3. I hereby declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true. I understand that willful false statements



Jennifer L. Calvert